We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+15.97%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$119M
AUM Growth
-$29.2M
Cap. Flow
-$43.3M
Cap. Flow %
-36.49%
Top 10 Hldgs %
54.42%
Holding
88
New
24
Increased
10
Reduced
14
Closed
37

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.54M
2
CEMP
Cempra, Inc.
CEMP
+$5.12M
3
ASND icon
Ascendis Pharma A/S
ASND
+$4.16M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$3.02M
5
FOLD
Amicus Therapeutics
FOLD
+$2.93M

Top Sells

Rank Stock Value
1
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$2.97M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$2.9M
3
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$2.74M
4
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$2.42M
5
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$2.3M

Sector Composition

Rank Sector Weight
1 Healthcare 80.05%
2 Consumer Discretionary 2.48%
3 Industrials 0.85%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGEN
51
Agenus
AGEN
$312M
– –
-13,678
Closed -$1.07M
ASMB icon
52
Assembly Biosciences
ASMB
$498M
– –
-317
Closed -$30K
ASRT
53
DELISTED
Assertio
ASRT
– –
-1,516
Closed -$1.47M
CERS icon
54
CALL
Cerus
CERS
$433M
– –
-200,000
Closed -$1.25M
EHTH icon
55
eHealth
EHTH
$42.2M
– –
-69,519
Closed -$1.73M
ENTA icon
56
Enanta Pharmaceuticals
ENTA
$366M
– –
-44,528
Closed -$2.26M
EYPT icon
57
EyePoint Inc
EYPT
$1.03B
– –
-12,234
Closed -$503K
HRTX icon
58
Heron Therapeutics
HRTX
$93.9M
– –
-101,050
Closed -$1.02M
NBIX icon
59
CALL
Neurocrine Biosciences
NBIX
$16.8B
– –
-31,500
Closed -$704K
OXM icon
60
Oxford Industries
OXM
$566M
– –
-24,742
Closed -$337K
QQQ icon
61
PUT
Invesco QQQ Trust
QQQ
$469B
– –
-70,000
Closed -$7.23M
VCYT icon
62
Veracyte
VCYT
$3.7B
– –
-29,024
Closed -$280K
VRTX icon
63
CALL
Vertex Pharmaceuticals
VRTX
$121B
– –
-20,000
Closed -$2.38M
XNCR icon
64
Xencor
XNCR
$1.5B
– –
-22,011
Closed -$353K
PRTK
65
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-29,252
Closed -$1.13M
ATRS
66
DELISTED
Antares Pharma, Inc.
ATRS
– –
-232,762
Closed -$598K
TRIL
67
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-19,000
Closed -$171K
GWPH
68
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-20,000
Closed -$1.35M
AMAG
69
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-26,596
Closed -$1.13M
TTPH
70
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-3,740
Closed -$2.97M
FWP
71
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-8,676
Closed -$1.26M
FRSH
72
DELISTED
Papa Murphy's Holdings, Inc
FRSH
– –
-140,462
Closed -$1.63M
HZNP
73
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-167,491
Closed -$2.16M
ATHN
74
PUT
DELISTED
Athenahealth, Inc.
ATHN
– –
-5,000
Closed -$729K
CYHHZ
75
DELISTED
Community Health Systems, Inc. Series A Contingent Value Rights
CYHHZ
– –
-2,963,721
Closed -$74K
1 2
3
4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2015 Portfolio in Review

As of Q1 2015, Acuta Capital Partners held 88 positions worth $119M, down 20% from $148M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Acuta Capital Partners withdrew a net $43.3M in Q1 2015, closing 37 positions and reducing 14 holdings. Its most notable exit was Tetraphase Pharmaceuticals, Inc., an estimated $2.97M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 48% a quarter earlier, followed by Consumer Discretionary and Industrials.

Against the trend, Acuta Capital Partners opened a new position in Iovance Biotherapeutics worth $8.1M.

  • Acuta Capital Partners's largest Q1 2015 buy was Iovance Biotherapeutics: 669,196 shares worth $8.1M.
  • Acuta Capital Partners added most to Amicus Therapeutics in Q1 2015, an estimated $2.93M increase.
  • Acuta Capital Partners's biggest Q1 2015 reduction was Pernix Therapeutics Holdings, Inc., cutting an estimated $2.42M.
  • Acuta Capital Partners fully exited Tetraphase Pharmaceuticals, Inc. in Q1 2015, selling an estimated $2.97M.
  • Acuta Capital Partners's ten largest holdings make up 54% of its $119M portfolio in Q1 2015.
  • Acuta Capital Partners opened 24 new positions and closed 37 in Q1 2015.
  • Acuta Capital Partners's portfolio value fell 20% quarter-over-quarter to $119M.

Based on Acuta Capital Partners's 13F filing for Q1 2015, filed 15 May 2015.